Novo Nordisk turns up the heat on inlicensed Genmab drug with phase III preparations
Despite the fact that Novo Nordisk has yet to publicize data from a phase II trial of hemophilia drug Mim8, which the company has developed through a license agreement with Genmab, recruitment for a future phase III study has already begun.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
At Novo Nordisk, preparations are being made to begin a phase III trial of candidate Mim8, which the Danish company hopes to make a blockbuster drug – a drug expected to reach sales of over USD 1bn a year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
